19 Comments
 

Moelis and PWP are not that distinguishable in terms of outcomes from Rx shops "above" them in WSO's estimation. The number of Rx analysts is so small that your personal profile i.e. school, GPA, GMAT/SAT become more salient to PE recruiting than prestige hair splitting. 

GHL/Gugg/JEFF Rx are somewhat less easy for PE recruiting but the credit world is sufficiently large and Rx analyst program world small that people get looks from pretty much all Rx programs. 

To OP's question, I have no clue about PFG on-cycle performance so they should just ask an analyst in the group they got an offer from. Comparing the two for re-recruiting for FT is also a black box to me. Having the EB name is good (but not because "it's an EB") and what you actually learn in your internship experience doesn't (or shouldn't, again I don't really have actual first-hand insight here) make you less valuable than your counterpart with an M&A internship.

I will say that Rx SA->FT tends to churn some because SAs from EVR/PJT/HL etc. tend to gun for PE analyst programs and that helps create opportunities for your Gugg Rx intern with their return offer in hand to get a top target group for on-cycle.

 

I think you also want to consider what do you want to do? Those shops are phenominal, just not cranking out 10bn dollar RX plans every Tuesday.

Reneging isn’t too bad, I’ve seen folk do it. Though that connection is definitely gone

 

I have heard some crazy horror stories about the consequences of reneging. Not sure how common these consequences are, but the names that you listed where you would reneg from are strong. I have a friend who interned in an EB doing private funds and he was able to land a PE spot for FT, so PE is definitely an attainable goal from your position.

 

Sorry would be too easy to identify who he is through linkedin, don't want to dox my friend on wso

 

Ut voluptate libero voluptas earum tempora in. Nulla minus ipsum vero distinctio voluptatem voluptatem. Sequi voluptatem consequatur unde officia recusandae. Facilis voluptas modi amet molestias reprehenderit ut officia.

Aperiam laborum pariatur eos aut impedit voluptas perferendis. Animi et aspernatur labore quia sunt. Molestiae et est possimus natus ipsa. Dignissimos qui similique quas.

Career Advancement Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

June 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Morgan Stanley 02 98.8%
  • Evercore 01 98.3%
  • BMO Capital Markets 12 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

June 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • JPMorgan 01 97.7%
  • Goldman Sachs 02 97.1%

Total Avg Compensation

June 2026 Investment Banking

  • Vice President (14) $434
  • Associates (44) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (79) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
GameTheory's picture
GameTheory
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
dosk17's picture
dosk17
98.9
9
DrApeman's picture
DrApeman
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”